Recombinant microorganism for obtaining alpha-farnesene and beta-farnesene and construction method thereof

By using α-farnesene synthase and its mutants from tea tree and pear, as well as β-farnesene synthase and its mutants from chamomile, and constructing recombinant microorganisms, the problems of single enzyme source and insufficient yield in farnesene synthesis were solved, achieving efficient farnesene production and meeting the needs of industrial and agricultural applications.

CN118956840APending Publication Date: 2024-11-15WUHAN HESHENG TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311847929.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2021-04-19
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The microbial synthesis of farnesene in existing technologies suffers from problems such as a single enzyme source and insufficient yield, especially the performance and yield of α-farnesene and β-farnesene synthases need to be improved.

Method used

We used α-farnesene synthase and its mutants from tea and pear, as well as β-farnesene synthase and its mutants from chamomile, and optimized gene copy number and MVA pathway gene expression by constructing recombinant microorganisms, combined with CRISPR-Cas9 gene editing technology to increase farnesene production.

Benefits of technology

It has achieved efficient production of farnesene, increased the yield of α-farnesene and β-farnesene, and reached a fermentation yield of up to 50 g/L in fermenters, meeting the needs of industrial and agricultural applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956840A_ABST
    Figure CN118956840A_ABST
Patent Text Reader

Abstract

The invention discloses a recombinant microorganism for obtaining alpha-farnesene and beta-farnesene and a construction method of the recombinant microorganism, and belongs to the field of synthetic biology. According to the invention, the alpha-farnesene synthase and the beta-farnesene synthase with excellent performance are obtained, and the alpha-farnesene synthase and the beta-farnesene synthase comprise the alpha-farnesene synthase or the beta-farnesene synthase with the sequence shown as SEQ ID NO.1-6. On the basis of CEN.PK2-1D, the recombinant microorganism provided by the invention contains five farnesene synthase genes, and also contains additional MVA pathway genes such as ERG10, ERG13, tHMG1, ERG12, ERG8, MVD1 and IDI1, as well as an additional ERG20 and a tHMG1 gene.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of synthetic biology, and in particular relates to a recombinant microorganism for obtaining α-farnesene and β-farnesene and a construction method thereof. Background Art

[0002] Farnesene is a sesquiterpene compound, which is widely used in agriculture and industrial production. At present, farnesene can be used as a substitute for existing petroleum-based diene monomers in the production of tackifying resins, which improves its softening point, stability and thermal stability. At the same time, farnesene is the main component of many plant volatile substances. According to the signal connection mechanism between plants and pests and the natural advantages of plant volatile substances in pest trapping, farnesene is often used as a pest attractant and combined with insect traps for agricultural production. Polymerized farnesene is also used as a gum base component to replace artificial polymers derived from petroleum raw materials. Since it is a food-acceptable polymer, it is also used in foods such as chewing gum base. Farnesene is currently obtained by plant extraction, chemical synthesis and biosynthesis. Microbial fermentation is not limited by factors such as plant growth and numerous impurities. It has low cost and less environmental pollution than chemical synthesis. It is an economical and green synthesis method.

[0003] At present, the microbial synthesis of farnesene mainly uses Escherichia coli, Saccharomyces cerevisiae, and Yarrowia lipolytica, and some progress has been made. The enzymes currently used to produce α-farnesene are basically derived from apples, while β-farnesene synthase is derived from Artemisia annua. Summary of the invention

[0004] One of the purposes of the present invention is to provide a farnesene synthase with excellent performance, and the use of the farnesene synthase in constructing a recombinant microorganism producing farnesene.

[0005] A farnesene synthase with excellent performance, which is an α-farnesene synthase or a β-farnesene synthase; wherein the α-farnesene synthase is an α-farnesene synthase derived from a tea tree with an amino acid sequence as shown in SEQ ID NO.1, or an α-farnesene synthase mutant containing one or two of the following mutations based on the α-farnesene synthase derived from a tea tree with an amino acid sequence as shown in SEQ ID NO.1: W281C, C455N; or the α-farnesene synthase is an α-farnesene synthase derived from a pear with an amino acid sequence as shown in SEQ ID NO.3, or an α-farnesene synthase mutant containing one or more of the following mutations based on the α-farnesene synthase derived from a pear with an amino acid sequence as shown in SEQ ID NO.3: G252E, D10G, A78T; the β-farnesene synthase is a β-farnesene synthase derived from a chamomile with an amino acid sequence as shown in SEQ ID NO.2, or an α-farnesene synthase mutant containing one or more of the following mutations based on the α-farnesene synthase derived from a pear with an amino acid sequence as shown in SEQ ID NO.3: G252E, D10G, A78T; the β-farnesene synthase is a β-farnesene synthase derived from a chamomile with an amino acid sequence as shown in SEQ ID NO.2, or an α-farnesene synthase mutant containing one or more of the following mutations based on the α-farnesene synthase derived from a pear with an amino acid sequence as shown in SEQ ID NO.3: A β-farnesene synthase mutant based on the chamomile-derived β-farnesene synthase shown in NO.2, containing one or more of the following mutations: F11S, M35T, T319S, I434T, I460V, K59R, S204Y.

[0006] The farnesene synthase has a more excellent performance in synthesizing farnesene, and can be used to produce farnesene or construct a recombinant microorganism that produces farnesene, thereby increasing the yield of farnesene.

[0007] The second object of the present invention is to provide a recombinant microorganism that produces farnesene, as well as a construction method of the recombinant microorganism and the application of the recombinant microorganism in producing farnesene.

[0008] A recombinant microorganism producing farnesene is a recombinant microorganism producing α-farnesene or a recombinant microorganism producing β-farnesene. The number of copies of genes in the recombinant microorganism producing α-farnesene is ERG10:ERG13:tHMG1:ERG12:ERG8:MVD1:IDI1:ERG20:aFS=2:2:X:2:2:2:2:2:X, where X is an integer greater than or equal to 1; the number of copies of genes in the recombinant microorganism producing β-farnesene is ERG10:ERG13:tHMG1:ERG12:ERG8:MVD1:IDI1:ERG20:bFS=2:2:X:2:2:2:2:2:X, where X is an integer greater than or equal to 1. Among them, ERG10 is a gene encoding acetoacetyl-CoA thiolase, ERG13 is a gene encoding HMG-CoA synthase, tHMG1 is a gene encoding HMG-CoA reductase, ERG12 is a gene encoding mevalonate kinase, ERG8 is a gene encoding mevalonate-5-phosphate kinase, MVD1 is a gene encoding mevalonate pyrophosphate decarboxylase, IDI1 is a gene encoding isoprene pyrophosphate isomerase, ERG20 is a gene encoding farnesene pyrophosphate synthase, aFS is a gene encoding α-farnesene synthase, and bFS is a gene encoding β-farnesene synthase. Preferably, the α-farnesene synthase encoded by aFS is an α-farnesene synthase derived from tea tree as shown in SEQ ID NO.1, or an α-farnesene synthase derived from pear as shown in SEQ ID NO.3, or a mutant of the above α-farnesene synthase; the β-farnesene synthase encoded by bFS is a β-farnesene synthase derived from chamomile as shown in SEQ ID NO.2, or a mutant of the above β-farnesene synthase; more preferably, the amino acid sequence of the α-farnesene synthase encoded by aFS is shown in SEQ ID NO.4 (based on the α-farnesene synthase derived from pear, containing the G252E mutation); the amino acid sequence of the β-farnesene synthase encoded by bFS is shown in SEQ ID NO.5 (based on the β-farnesene synthase derived from chamomile, containing the F11S, M35T, T319S, I434T, I460V mutations), or the amino acid sequence of the β-farnesene synthase encoded by bFS is shown in SEQ ID NO. As shown in NO.6 (based on the β-farnesene synthase derived from chamomile, it also contains F11S, M35T, T319S, I434T, I460V, K59R, and S204Y mutations).

[0009] More preferably, the Accession / GENE ids of ERG10, ERG13, tHMG1, ERG12, ERG8, MVD1, IDI1 and ERG20 in NCBI are shown in the table below.

[0010] Gene Accession / GENEid ERG10 856079 ERG13 854913 HkDJ 854900, truncated 4-1659 bp ERG12 NM_001182715.1 ERG8 CP046093.1, 689693..691048 MVD1 NM_001183220.1 IDI1 NM_001183931.1 ERG20 853272

[0011] Preferably, the farnesene-producing recombinant microorganism uses Saccharomyces cerevisiae as a host; more preferably, the farnesene-producing recombinant microorganism uses Saccharomyces cerevisiae CEN.PK2-1D strain as a host.

[0012] Preferably, the recombinant microorganism producing α-farnesene contains 5 genes encoding α-farnesene synthases shown in SEQ ID NO.3 or SEQ ID NO.4 based on Saccharomyces cerevisiae CEN.PK2-1D, contains additional MVA pathway genes (ERG10, ERG13, THMG1, ERG12, ERG8, MVD1, IDI1) and an additional ERG20 gene, and an additional tHMG1 gene. More preferably, the recombinant microorganism producing α-farnesene is obtained by transferring the genes shown in the following table into Saccharomyces cerevisiae CEN.PK2-1D via plasmids, so that the relevant genes are integrated into specific positions of the chromosomes of Saccharomyces cerevisiae CEN.PK2-1D.

[0013]

[0014] Preferably, the recombinant microorganism producing β-farnesene contains 5 genes encoding β-farnesene synthase shown in SEQ ID NO.5 or SEQ ID NO.6 based on Saccharomyces cerevisiae CEN.PK2-1D, contains additional MVA pathway genes (ERG10, ERG13, THMG1, ERG12, ERG8, MVD1, IDI1) and an additional ERG20 gene, and an additional tHMG1 gene. More preferably, the recombinant microorganism producing β-farnesene is obtained by transferring the genes shown in the following table into Saccharomyces cerevisiae CEN.PK2-1D via plasmids, so that the relevant genes are integrated into specific positions of the chromosomes of Saccharomyces cerevisiae CEN.PK2-1D.

[0015]

[0016]

[0017] In the above table, the sequences of the relevant promoters, genes or terminators are as follows:

[0018] >pTEF1:AGCTCATAGCTTCAAAATGTTTCTACTCCTTTTTTACTCTTCCAGATTTTCTCGGACTCCGCGCATCGCCGTACCACTTCAAAACACCCAAGCACAGCATACTAAATTTCCCCTCTTTTCCTCTAGGGTGTCGTTAATTACCCGTACTAAAGGTTTTGAAAAGAAAAAAGAGACCGCCTCGTTTCTTTTTCTTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTGAAAATTTTTTTTTTGATTTTTTTCTCTTTCGATGACCTCCCATTGATATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCATTTTTCTTGTTCTATTACAACTTTTTTTACTTCTTGCTCATTAGAAAGAAAGCATAGCAATCTAATCTAAGTTTTCTAGAACTAGTGGATCCCCCGGGaaaa;

[0019]

[0020] >tCYC1:TCATGTAATTAGTTATGTCACGCTTACATTCACGCCCTCCCCCCACATCCGCTCTAACCGAAAAGGAAGGAGTTAGACAACCTGAAGTCTAGGTCCCTATTTATTTTTTTATAGTTATGTTAGTATTAAGAACGTTATTTATATTTCAAATTTTTCTTTTTTTTCTGTACAGACGCGTGTACGCATGTAACATTATACTGAAAACCTTGCTTGAGAAGGTTTTGGGACGCTCGAAGGCTTTAATTTGC;

[0021] >tGAL10pGAL7:;

[0022] >tADH1:GCGAATTTCTTATGATTTATGATTTTTATTATTAAATAAGTTATAAAAAAAATAAGTGTATACAAATTTTAAAGTGACTCTTAGGTTTTAAAACGAAAATTCTTATTCTTGAGTAACTCTTTCCTGTAGGTCAGGTTGCTTTCTCAGGTATAGCATGAGGTCGCTCTTATTGACCACACCTCTACCGG;

[0023] >pGAL1pGAL10:;

[0024] >tHMG1:ACTTAGTCATACGTCATTGGTATTCTCTTGAAAAAGAAGCACAACAGCACCATGTGTTACGTAAAATATTTACTTTATAGTTTGTACGTCATAATTTCTTCCATATTACAAGTTCGTGCATATATAGAAAGAATTCTGTTGTTGTAATTGTCATAACTATTGAGCTTTACCTGAAAATTCAACGAAAAAAACTCAAAAACCACATGCTTCTCTTGAGTCATGCGGTTCCTTTCCCTTATGAGTGAAAATCTTCCTTTTTTAGCTATGTGCGCCATCCGATAAATGTAGGAGCAATGAAGC;

[0025] >tERG20:AACTAACGCTAATCGATAAAACATTAGATTTCAAACTAGATAAGGACCATGTATAAGAACTATATACTTCCAATATAATATAGTATAAGCTTTAAGATAGTATCTCTCGATCTACCGTTCCACGTGACTAGTCCAAGGATTTTTTTTAA;

[0026] >tPGK1:ATTGAATTGAATTGAAATCGATAGATCAATTTTTTTCTTTTCTCTTTCCCCATCCTTTTACGCTAAAATAATAGTTTATTTTATTTTTTGAATATTTTTTATTTATATACGTATATATAGACTATTATTTATCTTTTAATGATTATTAAGATTTTTATTAAAAAAAATTACGCTCCTCTTTTAATGCCTTTATGCAGTTTTTTTTTCCCATTCGATATTTCTATGTTCGGGTTCAGCGTATTTTAAGTTTAATAACTCGAAAATTCTGCGTTCGTT;

[0027] >pURA3: TTCAATTCATCATTTTTTTTTATTCTTTTTTTTGATTTCGGTTTCTTTGAAATTTTTTTGATTCGGTAATCTCCGAACAGAAGGAAGAACGAAGGAAGGAGCACAGACTTAGATTGGTATATATACGCATATGTAGTGTTGAAGAAACATGAAATTGCCCAGTATTCTTAACCCAACTGCACAGAACAAAAACCTGCAGGAAACGAAGATAAATC;

[0028] >tURA3: aaaactgtattataagtaaatgcatgtatactaaactcacaaattagagcttcaatttaattatatcagttattaccc.

[0029] Furthermore, the farnesene-producing recombinant microorganism can also have its GAL80 gene knocked out. After the Gal80 is knocked out, the strain can synthesize farnesene without adding galactose induction, which can reduce the experimental process and the fermentation cost.

[0030] The method for constructing the above-mentioned recombinant microorganism producing farnesene is to clone the genes ERG10, ERG13, tHMG1, ERG12, ERG8, MVD1, IDI1, ERG20, and Pyc-aFS / Mac-bFS into multiple plasmids, and then transfer the plasmids into the host, and obtain recombinant microorganisms expressing each gene after screening. Preferably, the method for constructing the recombinant microorganism producing farnesene comprises the following steps: constructing the plasmids shown in the above table, transferring the plasmids into Saccharomyces cerevisiae CEN.PK2-1D, integrating the relevant genes into the chromosome of Saccharomyces cerevisiae CEN.PK2-1D, and obtaining a recombinant microorganism producing farnesene.

[0031] The above-mentioned farnesene-producing recombinant microorganism can be used to produce farnesene.

[0032] The third object of the present invention is to provide a method for constructing a mutant strain library, which comprises the following steps: using a low-fidelity DNA polymerase taq polymerase and adjusting the magnesium ion concentration in the system to perform PCR amplification of key genes to obtain a DNA fragment containing a mutation, and cloning it into an expression vector. The expression vector obtained by the above construction is transferred into an expression host, such as Saccharomyces cerevisiae, and coated on a screening plate to obtain a mutant strain library.

[0033] The fourth object of the present invention is to provide a method for screening forward mutants of enzymes related to farnesene synthesis with high efficiency, comprising the following steps: inoculating from the above screening plate to a high-throughput seed culture plate (including but not limited to a 96-well plate, a 384-well plate), transferring to a fermentation culture plate (including but not limited to a 96-well plate, a 384-well plate) when the strain grows to the logarithmic growth phase, adding an extractant for high-throughput product extraction when the strain yield reaches the highest, transferring the extracted product to a new plate (including but not limited to a 96-well plate, a 384-well plate), adding a broad-spectrum color developer (including but not limited to iodine, vanillin concentrated sulfuric acid color developer, cerium molybdate, anisaldehyde, potassium permanganate), reacting (normal temperature or high temperature or low temperature, standing or shaking) for a sufficient time, and detecting the maximum absorption value with an ELISA instrument. Sequencing determines the positive mutation site. The present invention obtains an α-farnesene synthase or β-farnesene synthase mutant with improved performance containing one or more point mutations obtained by random mutation screening. Wherein, the extractant is isopropyl palmitate, white oil (liquid paraffin), methyl oleate or rapeseed oil. Using isopropyl palmitate, white oil (liquid paraffin) methyl oleate or rapeseed oil as an extractant will not affect the yield of farnesene. Based on this, the present invention also provides an application of an extractant in extracting farnesene.

[0034] The fifth object of the present invention is to provide a method for constructing a farnesene high-yield strain, which comprises the following steps: introducing a farnesene synthase containing at least one positive mutation into a chassis strain that can be used for farnesene production, and further improving the yield of farnesene by adjusting the ratio of the key gene tHMG1 of the MVA pathway and the farnesene synthase, thereby obtaining a farnesene high-yield strain. Thus, the recombinant microorganism can be used to culture and obtain a high yield of farnesene.

[0035] The sixth object of the present invention is to provide a method for constructing another high-yield strain of another product in one step based on a certain high-yield strain, comprising the following steps: using a strain with high yield of product A as a chassis, using the CRISPR gene editing method, gRNA targeting the product synthesis gene, donor DNA containing the product B synthesis gene, and realizing a one-time replacement of key genes through the CRISPR gene editing technology, thereby obtaining a strain with high yield of product B.

[0036] The present invention verifies and compares farnesene synthases from several different sources, and finds that the performance is better than the currently commonly used farnesene synthase. In addition, after engineering modification, a β-farnesene synthase with improved performance is obtained, and finally a high-yield farnesene synthesis yeast strain is obtained. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 This is a schematic diagram of the construction of plasmid pZY600.

[0038] Figure 2This is a schematic diagram of the construction of plasmid pZY413.

[0039] Figure 3 This is a schematic diagram of the construction of plasmid pZY412L.

[0040] Figure 4 This is a schematic diagram of the construction of plasmid pZY414.

[0041] Figure 5 This is a schematic diagram of the construction of plasmid pZY900.

[0042] Figure 6 This is a schematic diagram of the construction of plasmid AFS series and BFS series.

[0043] Figure 7 This is a graph showing the farnesene production results of fermentation with different strains.

[0044] Figure 8 It is a schematic diagram of the construction of plasmids pAFS1-P2, pAFS1-P3, pAFS1-P4, pAFS1-P5, pAFS1-P6, and pAFS1-P7.

[0045] Fig. 9 This is a graph showing the yield results of a high-yielding strain of β-farnesene. DETAILED DESCRIPTION

[0046] The following examples are used to further illustrate the present invention, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art.

[0047] Example 1 Construction of vectors required for chassis yeast strains

[0048] (1) Plasmid pZY600

[0049] The function of plasmid pZY600 is to integrate Cas9 protein so that the Crispr-cas9 gene editing technology can be used for strain modification. Figure 1 ), wherein pTEF1_Cas9_tCYC1 refers to Cas9 expressed under the control of TEF1 promoter, the terminator is cyc1, and the screening marker is Hygr, i.e., hygromycin; ΔchrXII-2 refers to the position of the chromosome into which the expression cassette is inserted.

[0050] The specific construction process of plasmid pZY600: using plasmid pZY403 as a template, primers G6001-F and G6001-R were used to amplify by PCR to obtain fragment G6001 (used to integrate the left and right arms of the ChrXII-2 site homologous to the Cas9 gene, introduce the NotI restriction site, and contain the plasmid backbone of ampicillin resistance and ura tags); using pZY403 as a template, primers G6002-F and G6002-R were used to amplify by PCR to obtain fragment G6002 (hygromycin resistance gene and its promoter TEF terminator TEF); using p43802 (addgene) as a template, primers G6003-F and G6003-R were used to amplify by PCR to obtain fragment G6003 (gene Cas9 and its promoter TEF1 terminator CYC1). The above fragments were recombined in Saccharomyces cerevisiae by DNA assemble (yeast assembly) to construct pZY600, and then amplified in Escherichia coli, and pZY600 was obtained after restriction enzyme digestion verification and sequencing. The fragment with the target gene was obtained after NotI restriction enzyme digestion and linearization, and its sequence is shown in SEQ ID NO.7.

[0051] Among them, the construction of plasmid pZY403 is as follows: using the yeast 30000B genome as a template, primers Z4031-F and Z4031-R were used to amplify the fragment Z4031 (for integrating the homologous left arm of the ChrXII-2 site of the ERG13 gene) by PCR; using the yeast 30000B genome as a template, primers Z4032-F and Z4032-R were used to amplify the fragment Z4032 (promoter) by PCR; using the yeast 30000B genome as a template, primers Z4033-F and Z4033-R were used to amplify the fragment Z4033 (ERG13 gene) by PCR; using the yeast 30000B genome as a template, primers Z4034-F and Z4034-R were used to amplify the fragment Z4034 (terminator) by PCR; plasmid pZY402 (see CN for details) was used. 111019850A) as a template, primers Z4035-F and Z4035-R were used to amplify the fragment Z4035 (screening marker) by PCR; the yeast 30000B genome was used as a template, primers Z4036-F and Z4036-R were used to amplify the fragment Z4036 (used to integrate the homologous right arm of the ChrXII-2 site of the ERG13 gene); pZY402 (see CN 111019850A for details) was used as a template, primers Z4037-F and Z4037-R were used to amplify the fragment Z4037 by PCR (introducing the NotI restriction site, containing the plasmid backbone of ampicillin resistance and ura tag); the above fragments were recombined in Saccharomyces cerevisiae by the DNAassemble method to construct pZY403, and then amplified in Escherichia coli, and pZY403 was obtained after restriction enzyme verification and sequencing.

[0052] The primer sequences used to construct the above plasmids are shown in the table below:

[0053]

[0054] (2) Plasmid pZY413 and gRNA plasmid pZY607

[0055] The function of plasmid pZY413 is to overexpress the relevant genes in the MVA pathway, providing an efficient FPP precursor synthesis chassis strain for subsequent gene screening. Related characteristics of plasmid pZY413: △ChrXI-3: ERG8_pGAL1pGAL10_tHMG1_pGAL7_ERG12( Figure 2 ), using promoters GAL1, GAL7, and GAL10 to control the expression of genes ERG8, ERG12, and THMG1, respectively, and the inserted chromosomal site is ChrXI-3.

[0056] The specific construction process of plasmid pZY413 is as follows: using plasmid pZY402 (see CN 111019850A for details) as a template, primers 4131-F and 4121-R were used to amplify by PCR to obtain fragment 4131 (for integrating the homologous right arms of ERG8, tHMG1, and ERG12 genes, introducing the NotI restriction site and a part of the plasmid backbone containing ampicillin resistance and ura tags); using pZY402 as a template, primers 4122-F and 4132-R were used to amplify by PCR to obtain fragment 4132 (the remaining part of the plasmid backbone containing ampicillin resistance and ura tags, for integrating the homologous right arms of the ChrXI-3 sites of the ERG8, tHMG1, and ERG12 genes) Using pZY402 as a template, primers 4133-F and 4133-R were used to amplify fragment 4133 (the remaining part of the homologous right arm of the ChrXI-3 site of ERG8, tHMG1, and ERG12 genes, and a part of the target genes ERG8, tHMG1, and ERG12 and their promoter terminators); using pZY402 as a template, primers 4134-F and 4134-R were used to amplify fragment 4134 (the remaining part of the target genes ERG8, tHMG1, and ERG12 and their promoter terminators). The above fragments were recombined in Saccharomyces cerevisiae to construct pZY413 by the DNAassemble method, and then amplified in Escherichia coli, and pZY413 was obtained after enzyme cutting verification and sequencing were correct. After linearization by NotI enzyme cutting, a fragment with the target gene was obtained, and its sequence is shown in SEQ ID NO.8.

[0057] pZY607 is a gRNA plasmid targeting the ChrXI-3 site, a tool plasmid for target recognition and cutting of Saccharomyces cerevisiae genomic DNA in Crispr-Cas9 gene editing technology. It is based on plasmid p43803 (http: / / www.addgene.org / 43803 / ) with the guide-RNA sequence replaced by atatgtctctaattttggaa. Using plasmid p43803 as a template, primers 6071-F and G6031-R were used to amplify fragment 6071 (a 20 bp target sequence for targeting recognition, gRNA scafold, terminator SUP4, and part of the plasmid backbone containing ampicillin resistance and ura tags) by PCR; using p43803 as a template, primers G6032-F and 6072-R were used to amplify fragment 6072 (the remaining part of the plasmid backbone containing ampicillin resistance and ura tags, a 20 bp target sequence for targeting recognition, and promoter SNR52). The above fragments were recombined in Saccharomyces cerevisiae by DNA assemble method to construct pZY607.

[0058] The primer sequences used to construct the above plasmids are shown in the table below:

[0059]

[0060] (3) Plasmid pZY412L and gRNA plasmid pZY606

[0061] The function of plasmid pZY412L is to overexpress the relevant genes in the MVA pathway, providing an efficient FPP precursor synthesis chassis strain for subsequent gene screening. Related characteristics of plasmid pZY412L: △ChrXII-4: IDI1_pGAL1pGAL10_ERG10_pGAL7_MVD1( Figure 3 ), using promoters GAL1, GAL7, and GAL10 to control the expression of genes IDI1, MVD1, and ERG10, respectively, and the inserted chromosomal site is ChrXII-4.

[0062] The specific construction process of plasmid pZY412L: primers 412-F and 412-R were used to obtain fragment pZY412SPD (a meaningless DNA sequence used to replace the g418 resistance gene in pZY410 (see CN 111019850A for details), containing sticky ends of SalI and SpeI restriction sites) by PCR without template denaturation annealing. The reaction system of this template-free denaturation annealing PCR is 10 μL, of which the primers are 4.5 μL respectively, and 10×T4 DNA ligase buffer is 1 μL. The following PCR program is set: 95°C, 5 min; touchdown PCR, 95°C, 1 min, -1°C / cycle, 70 cycles; 25°C, 5 min; 12°C, ∞ (the fragment can be taken out after template-free denaturation annealing PCR and can be temporarily stored at -40°C). pZY401 (see CN 111019850A for details) was digested with SalI and SpeI, and then the 12835 bp large fragment pZY412 VPD (containing the target genes MVD1, ERG10, IDI1, and the vector fragment of ampicillin resistance and ura selection markers) was recovered from the gel. The fragment pZY412 SPD and the fragment pZY412VPD were ligated with T4 DNA ligase at a molar ratio of 3:1 at 16°C overnight (about 20 hours), and the ligated product was transferred into E. coli DH10B competent cells for amplification. After enzyme digestion verification and sequencing, the plasmid pZY412L was obtained. After linearization with NotI, a fragment with the target gene was obtained, and its sequence is shown in SEQ ID NO.9.

[0063] pZY606 is a gRNA plasmid targeting Chr XII-4 site, a tool plasmid for target recognition and cutting of Saccharomyces cerevisiae genomic DNA in Crispr-Cas9 gene editing technology. It replaces the guide-RNA sequence with gcttcaagaattgagtaaac on the basis of plasmid p43803. Using plasmid p43803 as a template, primers 6061-F and G6031-R were used to amplify fragment 6061 (a 20bp target sequence for targeted recognition, gRNA scafold, terminator SUP4, and part of the plasmid backbone containing ampicillin resistance and ura tags) by PCR; using p43803 as a template, primers G6032-F and 6062-R were used to amplify fragment 6062 (the remaining part of the plasmid backbone containing ampicillin resistance and ura tags, a 20bp target sequence for targeted recognition, and promoter SNR52). The above fragments were recombined in Saccharomyces cerevisiae by the DNAassemble method to construct pZY606.

[0064] The primer sequences used to construct the above plasmids are shown in the table below:

[0065]

[0066] (4) Plasmid pZY414 and gRNA plasmid pZY608

[0067] The function of plasmid pZY414 is to overexpress the relevant genes in the MVA pathway, providing an efficient FPP precursor synthesis chassis strain for subsequent gene screening. The relevant characteristics of plasmid pZY414: △ChrX-3: pGAL1_ERG13_pGAL10_tHMG1, using promoters GAL1 and GAL10 to control the expression of genes ERG13 and THMG1 respectively, and the chromosome site of insertion is ChrX-3.

[0068] The specific construction process of plasmid pZY414 is as follows: using the genome of Saccharomyces cerevisiae strain CEN.PK2-1D (30000B) as a template, primers 4141-F and 4141-R were used to amplify fragment 4141 by PCR (for integrating the homologous right arm of the ChrX-3 site of ERG13 and tHMG1 genes, and introducing the NotI restriction site); using plasmid pRS426 as a template, primers 4142-F and 4142-R were used to amplify fragment 4142 by PCR (a plasmid backbone containing ampicillin resistance and ura tags); using the 30000B genome as a template, primers 4143-F and 4143-R were used to amplify fragment 4143 by PCR (for integrating the homologous right arm of the ChrX-3 site of ERG13 and tHMG1 genes, and introducing the NotI restriction site); using pZY410 (see CN for details) as a template, primers 4142-F and 4142-R were used to amplify fragment 4142 by PCR (a plasmid backbone containing ampicillin resistance and ura tags); using the 30000B genome as a template, primers 4143-F and 4143-R were used to amplify fragment 4143 by PCR (a fragment 4143 by PCR) 111019850A) was used as a template, and primers 4144-F and 4144-R were used to amplify the fragment 4144 (target genes ERG13, tHMG1 and their promoter and terminator) by PCR. The above fragments were recombined in Saccharomyces cerevisiae to construct pZY414 by the DNAassemble method, and then amplified in Escherichia coli, and after enzyme digestion verification and sequencing, the plasmid pZY414 was obtained. After NotI digestion and linearization, a fragment with the target gene was obtained, and its sequence is shown in SEQ ID NO.10.

[0069] pZY608 is a gRNA plasmid targeting the ChrX-3 site, a tool plasmid for target recognition and cutting of Saccharomyces cerevisiae genomic DNA in Crispr-Cas9 gene editing technology. It replaces the guide-RNA sequence with ctaatgtgtccgcgtttcta on the basis of plasmid p43803. Using plasmid p43803 as a template, primers 6081-F and G6031-R were used to amplify fragment 6081 (a 20bp target sequence for targeted recognition, gRNA scafold, terminator SUP4, and part of the plasmid backbone containing ampicillin resistance and ura tags) by PCR; using p43803 as a template, primers G6032-F and 6082-R were used to amplify fragment 6082 (the remaining part of the plasmid backbone containing ampicillin resistance and ura tags, a 20bp target sequence for targeted recognition, and promoter SNR52). The above fragments were recombined in Saccharomyces cerevisiae to construct pZY608 by the DNAassemble method, and then amplified in Escherichia coli. After enzyme digestion verification and sequencing, pZY608 was obtained.

[0070] The primer sequences used to construct the above plasmids are shown in the table below:

[0071]

[0072] Example 2 Chassis Yeast Strain Construction

[0073] The linearized fragment of plasmid pZY600 was transferred into the Saccharomyces cerevisiae strain CEN.PK2-1D and integrated into the chromosome by homologous recombination. The integration site was ChrXII-2 and the screening marker was hygromycin (Hygr). Thus, the background strain JCR1 was successfully constructed.

[0074] The linearized fragment of plasmid pZY413 was transformed into Saccharomyces cerevisiae JCR1 together with plasmid pZY607, and the selection marker was uracil (URA3). After 5-FOA counter-selection to remove the plasmid, strain JCR23 was obtained.

[0075] The linearized fragment of plasmid pZY414 was transformed into Saccharomyces cerevisiae JCR23 together with plasmid pZY608. The selection marker was uracil (URA3). After 5-FOA counter-selection to remove the plasmid, strain JCR25 was obtained.

[0076] The linearized fragment of plasmid pZY412L was transformed into Saccharomyces cerevisiae JCR25 together with plasmid pZY606. The selection marker was uracil (URA3). After 5-FOA counter-selection to remove the plasmid, strain JCR27 was obtained.

[0077]

[0078]

[0079] Example 3 Construction of expression vectors containing farnesene synthase from different sources

[0080] (1) Plasmid pZY900

[0081] Related features of plasmid pZY900: △LEU2:LEU2(URA3)_TCYC1_LacZ_pGAL10pGAL1_ERG20_tERG20( Figure 5 ), using promoters GAL1 and GAL10 to control the expression of genes ERG20 and LacZ respectively, the selection marker is Leu2, and the inserted chromosomal site is Leu2.

[0082] The specific construction process of plasmid pZY900 is as follows: using the yeast S288c genome as a template, 900-1F / 1R, 900-2F / 2R, 900-6F / 6R, and 900-7F / 7R were used to amplify fragments 9001 (the left homologous arm of Leu2), 9002 (terminator tTDH2), 9006 (gene ERG20 and terminator tERG20), and 9007 (the right arm of Leu2); using the yeast 30000B genome as a template, primers 900-3F / 3R and 900-5F / 5R were used to amplify fragments 9003 (terminator tCYC1) and 9005 (promoter pGAL1 and Pgal10) respectively; primers 900-8F / 8R were used to amplify the plasmid backbone (introducing MssI restriction site and screening marker). The above fragments were recombined in Saccharomyces cerevisiae by DNAassemble (yeast assembly) to construct pZY900, and then amplified in Escherichia coli. After enzyme digestion verification and sequencing, pZY900 was obtained, and the sequence is shown in SEQ ID NO.11.

[0083] The primer sequences used to construct the above plasmids are shown in the table below:

[0084]

[0085] (2) Plasmid AFS series, BFS series

[0086] △LEU2: LEU2(URA3)_TCYC1_TS_pGAL10pGAL1_ERG20_tERG20

[0087] The specific construction process of plasmids AFS and BFS: The amino acid sequences of α-farnesene synthase and β-farnesene synthase from different sources can be queried in GeneBank (Accession number is shown in the table below). The nucleotides encoding each enzyme have been optimized according to the codon preference of Saccharomyces cerevisiae, and the optimized sequences are synthesized by GenScript. Among them, the nucleotide sequence encoding α-farnesene synthase from pear is shown in SEQ ID NO.12, the nucleotide sequence encoding α-farnesene synthase from tea tree is shown in SEQ ID NO.13, and the nucleotide sequence encoding β-farnesene synthase from chamomile is shown in SEQ ID NO.14. The gene is amplified by PCR to make it have a BsaI restriction site, and then assembled with the universal plasmid pZY900 by Goden gate assembly to obtain an expression vector. The sources of farnesene synthase in plasmid pAFS1-6 are pear, cherry, poplar, castor, tea tree, and apple, respectively; the sources of farnesene synthase in plasmid pBFS1-8 are chamomile, sunflower, wild chrysanthemum, pyrethrum, cardoon, lettuce, artemisia annua, and Fusarium graminearum, respectively.

[0088]

[0089]

[0090] The primer sequences used to construct the above plasmids are shown in the table below:

[0091]

[0092]

[0093] Example 4 Construction of farnesene producing strain

[0094] The plasmids constructed in Example 3 were respectively transformed into strain JCR27, and the screening plate was Sc-ura (synthetic yeast nitrogen source YNB 6.7 g / L, glucose 20 g / L, mixed amino acid powder lacking uracil 1.3 g / L, 2% agar powder).

[0095] These strains were cultured by shake flask fermentation. The specific method was as follows: single colonies were picked from the transformation plates and placed in PA bottles containing 5 mL of seed culture medium. The seed culture medium formula was: YNB (6.7 g / L), yeast powder (10 g / L), glucose (20 g / L), and mixed amino acid powder lacking uracil (1.3 g / L). The seeds were cultured in a shaker at 30°C overnight and then transferred. 600 =0.1 transfer, after transfer, covered with 20% organic phase (n-dodecane or isopropyl myristate, isopropyl palmitate, white oil (liquid paraffin), methyl oleate or rapeseed oil) and placed in a shaker at 30°C to start shake flask fermentation. The fermentation medium formula is: peptone (20g / L), yeast powder (10g / L), glucose (10g / L), galactose (10g / L). After the fermentation is completed, samples are collected and the product composition is detected by GCMS of the organic phase. The products can be detected, α-farnesene synthase includes apple (Md-aFS), cherry (Pyr-aFS), pear (Pyc-aFS), tea tree (Cas-aFS), and poplar (Pot-aFS) sources, and β-farnesene synthase includes Artemisia annua (Aa-bFS), chamomile (Mac-bFS), wild chrysanthemum (Chi-aFS), and Fusarium graminearum (FgJ03939) sources. The yield results are as follows Figure 7 shown.

[0096] As far as we know, this is the first time that α-farnesene synthase from pear and tea tree has been expressed in a microorganism and the product has been successfully detected. It is also the first time that β-farnesene synthase from wild chrysanthemum has been expressed in a microorganism and the product has been successfully detected. The α-farnesene synthase from pear and the β-farnesene synthase from chamomile have higher activity, and the α-farnesene synthase from tea tree, which has not been heterologously expressed in previous studies, also has good performance.

[0097] Example 5 Construction of a farnesene synthase mutant library

[0098] The method adopted was random mutagenesis, that is, primers were designed, low-fidelity DNA polymerase was used to amplify the farnesene synthesis gene, the magnesium ion concentration was adjusted (2mM-12mM), key genes were amplified by PCR, a DNA fragment containing the mutation was obtained, and it was transferred into the strain JCR27 together with the expression vector pZY900 (after BsaI cutting) through the lithium acetate transformation method. The strain containing the mutant was obtained by yeast assembly and coated with Sc-ura screening plates.

[0099] For the random mutation of α-farnesene synthase from pear, the primers were pAFS1-mutation-F and pAFS1-mutation-R; for the random mutation of β-farnesene synthase from chamomile, the primers were pBFS1-mutation-F and pBFS1-mutation-R; for the random mutation of α-farnesene synthase from tea tree, the primers were pAFS5-mutation-F and pAFS5-mutation-R.

[0100] The primer sequences are shown in the table below:

[0101]

[0102]

[0103] Example 6 High-throughput screening and characterization of strains containing farnesene synthase mutants

[0104] Select positive clones on the plate in Example 5 to a high-throughput seed culture plate containing Sc-ura defective medium, select a strain containing wild-type farnesene synthase as a control, culture at 999rpm and 30°C, transfer to a fermentation culture plate containing fermentation medium when the strain grows to the logarithmic growth phase, add a covering agent to reduce the volatilization of the product, and wait until the strain yield reaches the highest, add an extractant (n-dodecane, isopropyl myristate, liquid paraffin, white oil, isopropyl palmitate) for high-throughput product extraction, transfer the extracted product to a new plate, add a broad-spectrum color developer (vanillin concentrated sulfuric acid color developer), react (65°C, 20min), and detect the maximum absorption value with an ELISA instrument. Select a strain with an absorbance higher than the wild type, extract the yeast plasmid, transfer to Escherichia coli for amplification, and extract the plasmid, and determine the positive mutation site by first-generation sequencing. The results showed that for β-farnesene synthase from chamomile, amino acid mutations that improve enzyme activity include the following: F11S, M35T, T319S, I434T, I460V, K59R, and S204Y. The yield increase times are shown in the table below.

[0105]

[0106] The obtained beneficial mutations were combined in various ways, and the obtained plasmids were transferred into strain JCR27. After further evaluation by 96-well plate fermentation, the combination with the largest increase in multiples was finally obtained, among which pBFS45 (F11S, M35T, T319S, I434T, I460V) and pBFS46 (F11S, M35T, T319S, I434T, I460V, K59R, S204Y) had the largest increase in yield. The yield of the optimal mutant of β-farnesene synthase was nearly 2 times higher than that of the wild type, reaching 430 mg / L and 470 mg / L, respectively. The yields of the two mutants were similar, so these two mutants were selected for subsequent construction.

[0107] The process of constructing plasmid pBFS45 is as follows. Mac-bFS-I460V was amplified from pBFS20 plasmid (i.e., pBFS20 plasmid was used as template, the same below) using primers pBFS1-1F / pBFS45-2R, Mac-bFS-I434T was amplified from pBFS18 plasmid using primers pBFS45-3F / R, Mac-bFS-T319S was amplified from pBFS15 plasmid using primers pBFS45-4F / R, Mac-bFS-M35T was amplified from pBFS12 plasmid using primers pBFS45-5F / R, and Mac-bFS-F11S was amplified from pBFS9 plasmid using primers pBFS45-6F / R. These fragments were then connected by overlap extension PCR and cloned into pZY900 by the Golden Gate assembly method to obtain plasmid pBFS45.

[0108] The primer sequences used to construct plasmid pBFS45 are shown in the table below:

[0109]

[0110]

[0111] The process of constructing plasmid pBFS46 is as follows. Mac-bFS-A1341G was amplified from pBFS45 plasmid (i.e., pBFS45 plasmid was used as template, the same below) using primers pBFS1-1F / pBFS46-1R, Mac-bFS-S204Y was amplified from pBFS45 plasmid using primers pBFS46-2F / R, Mac-bFS-K59R was amplified from pBFS45 plasmid using primers pBFS46-3F / R, and Mac-bFS-K59R was amplified from pBFS45 plasmid using primers pBFS46-4F / pBFS45-6R. These fragments were then connected by overlap extension PCR and cloned into pZY900 by Golden Gate assembly to obtain plasmid pBFS46.

[0112] The primer sequences used to construct plasmid pBFS46 are shown in the table below:

[0113]

[0114] The same mutation method was used to screen the α-farnesene synthase from pear and tea tree sources, and the results of the improved mutants from pear are as follows.

[0115]

[0116] The yield of the mutant derived from tea tree was 1.52 times that of the wild type, and the shake flask yield reached 257.85 mg / L.

[0117]

[0118] Example 7 Construction of plasmids required for farnesene high-yielding strains

[0119] (1) To achieve high yield of α-farnesene, plasmids pAFS1-P2, pAFS1-P3, pAFS1-P4, pAFS1-P5, pAFS1-P6, and pAFS1-P7 were constructed. The schematic diagram of the construction of these plasmids is shown in Figure 8 .

[0120] The α-farnesene synthase gene from pear was synthesized by GenScript Co., Ltd. according to the codon optimization of Saccharomyces cerevisiae (SEQ ID NO. 12). The obtained plasmid was used as the template required for Pyc-afs gene amplification.

[0121] Ura3 left arm, tCYC1, pGAL10-pGAL1, tPGK1, and Ura3 right arm were amplified from CEN.PK2-1D (CEN.PK2-1D yeast genomic DNA, the same below) using primers pAFS1-P2-1F / R, pAFS1-P2-3F / R, pAFS1-P2-5F / R, pAFS1-P2-7F / R, and pAFS1-P2-8F / R. His3 marker was amplified from pRS423 plasmid using primers pAFS1-P2-2F / R, tHMG1 was amplified from S288C (S288C yeast genomic DNA, the same below) using primers pAFS1-P2-4F / R, Pyc-aFS was amplified from pRS426 plasmid using primers pAFS1-P2-6F / R, and the plasmid backbone was amplified from pRS426 plasmid using primers pAFS1-P2-9F / R. These fragments were then assembled by the DNA assemble method to obtain pAFS1-P2.

[0122] Ura3 left arm, tCYC1, pGAL10-pGAL1, tPGK1, and Ura3 right arm were amplified from CEN.PK2-1D using primers pAFS1-P2-1F / R, pAFS1-P2-3F / pAFS1-P3-3R, pAFS1-P3-5F / pAFS1-P2-5R, pAFS1-P2-7F / R, and pAFS1-P2-8F / R. His3 marker was amplified from pRS423 using primers pAFS1-P2-2F / R. Pyc-aFS was amplified from pRS423 using primers pAFS1-P2-6F / R. The plasmid backbone was amplified from pRS426 using primers pAFS1-P2-9F / R. These fragments were then assembled to obtain pAFS1-P3.

[0123] Ura3 left arm, tCYC1, pGAL10-pGAL1, tPGK1, and Ura3 right arm were amplified from CEN.PK2-1D using primers pAFS1-P2-1F / R, pAFS1-P2-3F / pAFS1-P4-3R, pAFS1-P4-5F / pAFS1-P2-5R, pAFS1-P2-7F / R, and pAFS1-P2-8F / R. His3 marker was amplified from pRS423 using primers pAFS1-P2-2F / R, Pyc-aFS was amplified from pRS423 using primers pAFS1-P4-4F / R and pAFS1-P2-6F / R, and the plasmid backbone was amplified from pRS426 using primers pAFS1-P2-9F / R. These fragments were then assembled to obtain pAFS1-P4.

[0124] YPRCdelta15 left arm, tCYC1, pGAL10-pGAL1, tPGK1, and YPRCdelta15 right arm were amplified from CEN.PK2-1D using primers pAFS1-P5-1F / R, pAFS1-P5-3F / R, pAFS1-P5-5F / R, pAFS1-P5-7F / R, and pAFS1-P5-8F / R. Trp1 marker was amplified from pRS424 using primers pAFS1-P5-2F / R, Pyc-aFS was amplified from pRS424 using primers pAFS1-P5-4F / R and pAFS1-P5-6F / R, and the plasmid backbone was amplified from pRS426 using primers pAFS1-P5-9F / R. These fragments were then assembled to obtain pAFS1-P5.

[0125] YPRCdelta15 left arm, pGAL10-pGAL1, tPGK1, and YPRCdelta15 right arm were amplified from CEN.PK2-1D using primers pAFS1-P5-1F / R, pAFS1-P6-5F / pAFS1-P5-5R, pAFS1-P5-7F / R, and pAFS1-P5-8F / R. Trp1 marker was amplified from pRS424 using primers pAFS1-P5-2F / pAFS1-P6-2R, tGPM1 was amplified from S288C using primers pAFS1-P6-3F / R, Pyc-aFS was amplified from primers pAFS1-P5-6F / R, and plasmid backbone was amplified from pRS426 using primers pAFS1-P5-9F / R. These fragments were then assembled to obtain pAFS1-P6.

[0126] YPRCdelta15 left arm, tCYC1, pGAL10-pGAL1, tPGK1, and YPRCdelta15 right arm were amplified from CEN.PK2-1D using primers pAFS1-P5-1F / R, pAFS1-P5-3F / pAFS1-P7-3R, pAFS1-P7-5F / pAFS1-P5-5R, pAFS1-P5-7F / R, and pAFS1-P5-8F / R. Trp1 marker was amplified from pRS424 using primers pAFS1-P5-2F / R, tHMG1 was amplified from S288C using primers pAFS1-P7-4F / R, Pyc-aFS was amplified from pRS426 using primers pAFS1-P5-9F / R, and these fragments were then assembled to obtain pAFS1-P7.

[0127] The primer sequences used to construct the above plasmids are shown in the table below:

[0128]

[0129]

[0130]

[0131]

[0132] The construction process of pAFS38-P2, pAFS38-P3, pAFS38-P4, pAFS38-P5, pAFS38-P6, and pAFS38-P7 was the same as that of pAFS1-P2, pAFS1-P3, pAFS1-P4, pAFS1-P5, pAFS1-P6, and pAFS1-P7, except that the template pAFS1 used in the construction of pAFS1-P2, pAFS1-P3, pAFS1-P4, pAFS1-P5, pAFS1-P6, and pAFS1-P7 was replaced by pAFS38.

[0133] (2) To achieve high production of β-farnesene, plasmids pBFS45, pBFS45-P2, pBFS45-P3, pBFS45-P4, pBFS45-P5, pBFS45-P6, and pBFS45-P7 were constructed. Plasmids pBFS46, pBFS46-P2, pBFS46-P3, pBFS46-P4, pBFS46-P5, pBFS46-P6, and pBFS46-P7 were constructed.

[0134] The construction of plasmid pBFS45 is shown in Example 6.

[0135] Ura3 left arm, tCYC1, pGAL10-pGAL1, tPGK1, and Ura3 right arm were amplified from CEN.PK2-1D using primers pAFS1-P2-1F / R, pAFS1-P2-3F / R, pAFS1-P2-5F / pBFS45-P2-5R, pBFS45-P2-7F / pAFS1-P2-7R, and pAFS1-P2-8F / R. His3 marker was amplified from pRS423 using primers pAFS1-P2-2F / R, tHMG1 was amplified from S288C using primers pAFS1-P2-4F / R, Mac-bFS (F11S, M35T, T319S, I434T, I460V) was amplified from pBFS45 using primers pBFS45-P2-6F / pBFS45-P2-6R, and the plasmid backbone was amplified from pRS426 using primers pAFS1-P2-9F / R. These fragments were then assembled to obtain pBFS45-P2.

[0136] Ura3 left arm, tCYC1, pGAL10-pGAL1, tPGK1, and Ura3 right arm were amplified from CEN.PK2-1D using primers pAFS1-P2-1F / R, pAFS1-P2-3F / pAFS1-P3-3R, pAFS1-P3-5F / pBFS45-P3-5R, pBFS45-P3-7F / pAFS1-P2-7R, and pAFS1-P2-8F / R, and His3 was amplified from pRS423 using primers pAFS1-P2-2F / R. marker, Mac-bFS (F11S, M35T, T319S, I434T, I460V) was amplified with primers pBFS45-P3-6F / R, and the plasmid backbone was amplified from pRS426 with primers pAFS1-P2-9F / R, and these fragments were subsequently assembled to obtain pBFS45-P3.

[0137] Ura3 left arm, tCYC1, pGAL10-pGAL1, tPGK1, and Ura3 right arm were amplified from CEN.PK2-1D using primers pAFS1-P2-1F / R, pAFS1-P2-3F / pBFS45-P4-3R, pBFS45-P4-5F / pBFS45-P4-5R, pBFS45-P4-7F / pAFS1-P2-7R, and pAFS1-P2-8F / R. His3 marker was amplified from pRS423 using primers pAFS1-P2-2F / R, Mac-bFS (F11S, M35T, T319S, I434T, I460V) was amplified from pBFS45 using primers pBFS45-P4-4F / R and pBFS45-P4-6F / R, and the plasmid backbone was amplified from pRS426 using primers pAFS1-P2-9F / R. These fragments were then assembled to obtain pBFS45-P4.

[0138] YPRCdelta15 left arm, tCYC1, pGAL10-pGAL1, tPGK1, and YPRCdelta15 right arm were amplified from CEN.PK2-1D using primers pAFS1-P5-1F / R, pAFS1-P5-3F / pAFS1-P7-3R, pAFS1-P7-5F / pBFS45-P5-5R, pBFS45-P5-7F / pAFS1-P5-7R, and pAFS1-P5-8F / R. Trp1 marker was amplified from pRS424 using primers pAFS1-P5-2F / R, tHMG1 was amplified from S288C using primers pAFS1-P7-4F / pAFS1-P7-4R, Mac-bFS (F11S, M35T, T319S, I434T, I460V) was amplified from pBFS45 using primers pBFS45-P5-6F / R, and the plasmid backbone was amplified from pRS426 using primers pAFS1-P5-9F / R. These fragments were then assembled to obtain pBFS45-P5.

[0139] YPRCdelta15 left arm, pGAL10-pGAL1, tPGK1, and YPRCdelta15 right arm were amplified from CEN.PK2-1D using primers pAFS1-P5-1F / R, pAFS1-P6-5F / pBFS45-P6-5R, pBFS45-P6-7F / pAFS1-P5-7R, and pAFS1-P5-8F / R. Trp1 marker was amplified from pRS424 using primers pAFS1-P5-2F / pAFS1-P6-2R, tGPM1 was amplified from S288C using primers pAFS1-P6-3F / R, Mac-bFS (F11S, M35T, T319S, I434T, I460V) was amplified from pBFS45 using primers pBFS45-P6-6F / R, and the plasmid backbone was amplified from pRS426 using primers pAFS1-P5-9F / R. These fragments were then assembled to obtain pBFS45-P6.

[0140] YPRCdelta15 left arm, tCYC1, pGAL10-pGAL1, tPGK1, and YPRCdelta15 right arm were amplified from CEN.PK2-1D using primers pAFS1-P5-1F / R, pAFS1-P5-3F / pBFS45-P7-3R, pBFS45-P7-5F / R, pBFS45-P7-7F / pAFS1-P5-7R, and pAFS1-P5-8F / R. Trp1 marker was amplified from pRS424 using primers pAFS1-P5-2F / R, Mac-bFS (F11S, M35T, T319S, I434T, I460V) was amplified from pBFS45 using primers pBFS45-P7-4F / R and pBFS45-P7-6F / R, and the plasmid backbone was amplified from pRS426 using primers pAFS1-P5-9F / R. These fragments were then assembled to obtain pBFS45-P7.

[0141] The construction of plasmid pBFS46 is shown in Example 6.

[0142] The construction process of pBFS46-P2, pBFS46-P3, pBFS46-P4, pBFS46-P5, pBFS46-P6, and pBFS46-P7 is the same as that of pBFS45-P2, pBFS45-P3, pBFS45-P4, pBFS45-P5, pBFS45-P6, and pBFS45-P7, except that the template pBFS45 used in the construction of pBFS45-P2, pBFS45-P3, pBFS45-P4, pBFS45-P5, pBFS45-P6, and pBFS45-P7 was replaced with pBFS46.

[0143] Among them, the nucleotide sequence of Mac-bFS containing F11S, M35T, T319S, I434T, and I460V mutations optimized according to Saccharomyces cerevisiae codons is shown in SEQ ID NO.16; the nucleotide sequence of Mac-bFS containing F11S, M35T, T319S, I434T, I460V, K59R, and S204Y mutations optimized according to Saccharomyces cerevisiae codons is shown in SEQ ID NO.17.

[0144] The primer sequences used to construct the above plasmids are shown in the table below:

[0145]

[0146]

[0147]

[0148]

[0149] Example 8 Construction of β-farnesene high-yielding strain

[0150] The plasmid pBFS45 was linearized with Msi, and the fragment with the target gene was recovered and transformed into Saccharomyces cerevisiae JCR27. It was integrated into the chromosome according to homologous recombination. The integration site was LEU2 and the screening marker was leucine. The strain JVA122 was constructed. The plasmids pBFS45-P2, pBFS45-P3, and pBFS45-P4 were linearized, and the fragment with the target gene was recovered and transformed into Saccharomyces cerevisiae JVA122 respectively. It was integrated into the chromosome according to homologous recombination. The integration site was URA3 and the screening marker was histidine. The strains JVA124, JVA125, and JVA129 were constructed. pBFS45-P5 was linearized, and the fragments with the target gene were recovered and transformed into Saccharomyces cerevisiae JVA124, JVA125, and JVA129, respectively, and integrated into the chromosome according to homologous recombination, and the integration site was YPRCdelta15, and the screening marker was tryptophan, and strains JVA127, JVA130, and JVA134 were constructed. pBFS45-P6 was linearized, and the fragments with the target gene were recovered and transformed into Saccharomyces cerevisiae JVA124, JVA125, and JVA129, respectively, and integrated into the chromosome according to homologous recombination, and the integration site was YPRCdelta15, and the screening marker was tryptophan, and strains JVA128, JVA131, and JVA135 were constructed. pBFS45-P7 was linearized, and the fragments with the target gene were recovered and transformed into Saccharomyces cerevisiae JVA124, JVA125, and JVA129, respectively. The fragments were integrated into the chromosomes according to homologous recombination, and the integration site was YPRCdelta15. The screening marker was tryptophan. The strains JVA127, JVA138, and JVA139 were constructed. After shake flask fermentation, these strains all showed good performance, and the yield of β-farnesene reached a high level, ranging from 200 mg / L to 800 mg / L ( Fig. 9 The strain JVA139 with the highest yield was selected to knock out the GAL80 gene (construction of the knockout box pZY521: using the genome of yeast 30000B as a template, using primers 5201-F / 5211-R to amplify the left homology arm of GAL80; using pZY900 as a template, using primers 5212-F / 5212-R to amplify the selection marker URA3; using primers 5213-F / 5203-R to amplify the right homology arm of GAL80;) to eliminate the use of galactose in the fermentation process, and construct the strain JVA140.

[0151] The above primer sequences are shown in the table below:

[0152] Primers Sequence (5'-3') 5201-F caatggtctaggtagtggcattcg 5211-R CGACTCACTATAGGGCGAATTGGGTACgacggggagtggaaagaacgg 5212-F tcccgttctttccactcccgtcGTACCCAATTCGCCCTATAGTGAG 5212-R gccaagcacagggcaagatgcttTCACAGCTTGTCTGTAAGCGGA 5213-F GCATCCGCTTACAGACAAGCTGTGAaagcatcttgccctgtgctt 5203-R gagaccaccaagaatacagaagctattat

[0153] Depend on Fig. 9 It can be seen that there are obvious differences in yield between strains containing different numbers of genes (Thmg1 and farnesene synthase). In the strains without knocking out gal80, based on the wild-type strain CEN.PK2-1D, the strains containing 5 β-farnesene synthases, additional MVA pathway genes (ERG10, ERG13, THMG1, ERG12, ERG8, MVD1, IDI1) and an additional ERG20, and an additional Thmg1 have the highest β-farnesene yield. Therefore, adjusting the ratio of Thmg1 to farnesene synthase is of great significance for high yield.

[0154] Similarly, the linearized plasmids pBFS46, pBFS46-P4, and pBFS46-P7 were sequentially transformed into strain JCR27 to obtain strain JVA139-pBFS46, and the knockout construction of the GAL80 gene was performed to obtain strain JVA140-pBFS46.

[0155] Example 9 Construction of α-farnesene high-yielding strain

[0156] The α-farnesene high-yield strain can be constructed by traditional homologous recombination, similar to the construction of the β-farnesene high-yield strain in Example 8, and the corresponding strains JSA126-JSA138 can be constructed. The obtained high-yield β-farnesene strain can also be used as a chassis, and the crispr-cas9 gene editing technology is used to replace the β-farnesene synthase with α-farnesene synthase at one time to obtain a high-yield α-farnesene synthase strain. The construction process of the plasmid pAFS-gRNA: Using the plasmid pKlURA3 as a template, primers pAFS-gRNA-F and pAFS-gRNA-R are used to amplify PD pAFS-gRNA by PCR, and pCAS9 is used as the vector backbone. The Golden Gate method is used to construct the plasmid pAFS-gRNA, and after enzyme verification and sequencing are correct, pAFS-gRNA is obtained.

[0157] The above primer sequences are shown in the table below:

[0158] Primers Sequence (5'-3') pAFS-gRNA-F aaaggtctcaGATCGCTGGCATCAACAATGGGAAGTTTTAGAGCTAGAAATAGCA pAFS-gRNA-R AAAGGTCTCAAAACTCTAGACTTTTTCGATGATGTAGTTTCT

[0159] The plasmids pAFS1, pAFS1-P4, and pAFS1-P5 were linearized, and the fragments carrying the target gene were recovered and corresponding to the plasmids constructed for the β-farnesene high-producing strain (pAFS1 vs pBFS45, pAFS1-P4 vs pBFS45-P4, pAFS1-P5 vs pBFS45-P7), and were transferred into the strain JVA139 together with pAFS-gRNA. The screening marker was uracil. After a single clone was grown, it was streaked on a 5-FOA plate to construct the strain JSA132Crispr.

[0160] After shake flask fermentation, the strain JSA132Crispr can achieve a high level of α-farnesene production, with a yield of 473±35mg / L. The GAL80 gene was knocked out (construction of knockout cassette pZY521: using the genome of yeast 30000B as a template, using primers 5201-F / 5211-R to amplify the left homologous arm of GAL80; using pZY900 as a template, using primers 5212-F / 5212-R to amplify the screening marker URA3; using primers 5213-F / 5203-R to amplify the right homologous arm of GAL80;) to eliminate the use of galactose in the fermentation process, strain JSA145 was constructed, with a shake flask yield of 520mg / L. Strain JSA145, based on the wild-type strain CEN.PK2-1D, contains five α-farnesene synthases (Pyc-aFS), additional MVA pathway genes (ERG10, ERG13, THMG1, ERG12, ERG8, MVD1, IDI1), an additional ERG20, an additional Thmg1, and the GAL80 gene has been knocked out.

[0161] Similarly, linearized plasmids pAFS38, pAFS38-P4, and pAFS38-P5 were used to recover the fragments with the target gene, corresponding to the plasmids for constructing β-farnesene high-yield strains (pAFS38 vs pBFS45, pAFS38-P4 vs pBFS45-P4, pAFS38-P5 vs pBFS45-P7), and transferred into strain JVA139 together with pAFS-gRNA. The screening marker was uracil. After growing a single clone, the 5-FOA plate was streaked to construct strain JSA132-pAFS38-Crispr, with a shake flask yield of 580 mg / L. The knockout construction of the GAL80 gene was performed to obtain strain JSA145-pAFS38-Crispr, with a shake flask yield of 598 mg / L. The strain JSA145-pAFS38-Crispr contains 5 α-farnesene synthase (Pyc-aFS(G252E)) genes (SEQ ID NO.18) based on the wild-type strain CEN.PK2-1D, additional MVA pathway genes (ERG10, ERG13, THMG1, ERG12, ERG8, MVD1, IDI1), an additional ERG20, an additional Thmg1, and the GAL80 gene is knocked out.

[0162] Example 10 Fermentation tank fermentation of farnesene high-yielding strain

[0163] The fermentation medium described in reference (van Hoek, P.; de Hulster, E.; van Dijken, JP; Pronk, JTFermentative capacity in high-cell-density fed-batch cultures of baker's east. Biotechnol. Bioeng. 2000, 68, 517-523.) is used to carry out batch feeding fermentation on the constructed strains, α-farnesene synthesis strains, and β-farnesene strains (strains JSA145, JSA145-pAFS38-Crispr, JVA140, and JVA140-pBFS46). During the fermentation process, a covering agent is added to realize in-situ extraction. The covering agent can be n-dodecane, isopropyl myristate, isopropyl palmitate, liquid paraffin, and white oil. During the fermentation process, the dissolved oxygen is controlled to be above 20%, the pH is 5, the glucose concentration is 1-2 g / L, and the ethanol concentration is 5-10 g / L. Finally, in the fermentation tank, the α-farnesene production of strain JSA145 reached 28g / L, and the α-farnesene production of strain JSA145-pAFS38-Crispr reached 36g / L. The β-farnesene production of strain JVA140 reached 50g / L, and the β-farnesene production of strain JVA140-pBFS46 reached 55g / L.

[0164] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A farnesene synthase, characterized in that: The farnesene synthase is a β-farnesene synthase mutant, The β-farnesene synthase is based on the β-farnesene synthase derived from chamomile with an amino acid sequence as shown in SEQ ID NO.2, and is a β-farnesene synthase mutant containing one or more of the following mutations: F11S, M35T, T319S, I434T, I460V, K59R, and S204Y.

2. Use of the farnesene synthase according to claim 1 in producing farnesene or constructing a recombinant microorganism producing farnesene.

3. A recombinant microorganism producing farnesene, characterized in that: The recombinant microorganism is a recombinant microorganism that produces β-farnesene; The copy number of the gene in the recombinant microorganism producing β-farnesene is ERG10:ERG13:tHMG1:ERG12:ERG8:MVD1:IDI1:ERG20:bFS=2:2:X:2:2:2:2:2:X, where X is an integer greater than or equal to 1. Among them, ERG10 is a gene encoding acetoacetyl-CoA thiolase, ERG13 is a gene encoding HMG-CoA synthase, tHMG1 is a gene encoding HMG-CoA reductase, ERG12 is a gene encoding mevalonate kinase, ERG8 is a gene encoding mevalonate-5-phosphate kinase, MVD1 is a gene encoding mevalonate pyrophosphate decarboxylase, IDI1 is a gene encoding isoprene pyrophosphate isomerase, ERG20 is a gene encoding farnesene pyrophosphate synthase, and bFS is a gene encoding β-farnesene synthase, and the β-farnesene synthase is the β-farnesene synthase mutant described in claim 1.

4. The farnesene-producing recombinant microorganism according to claim 3, characterized in that: The amino acid sequence of β-farnesene synthase encoded by bFS is shown in SEQ ID NO.5 or SEQ ID NO.

6.

5. The farnesene-producing recombinant microorganism according to claim 3, characterized in that: The recombinant microorganism uses saccharomyces cerevisiae as a host.

6. The farnesene-producing recombinant microorganism according to claim 3, characterized in that: The recombinant microorganism producing β-farnesene contains 5 genes encoding β-farnesene synthase shown in SEQ ID NO.5 or SEQ ID NO.6 on the basis of Saccharomyces cerevisiae CEN.PK2-1D, contains additional MVA pathway genes ERG10, ERG13, THMG1, ERG12, ERG8, MVD1, IDI1, as well as an additional ERG20 gene and an additional tHMG1 gene.

7. The farnesene-producing recombinant microorganism according to any one of claims 3 to 6, characterized in that: The recombinant microorganism has the GAL80 gene knocked out.

8. The method for constructing a farnesene-producing recombinant microorganism according to any one of claims 3 to 7, characterized in that: The construction method is to clone genes ERG10, ERG13, tHMG1, ERG12, ERG8, MVD1, IDI1, ERG20, and Mac-bFS into multiple plasmids, then transfer the linearized fragments containing the target genes into the host, and obtain recombinant microorganisms expressing each gene through screening.

9. Use of the farnesene-producing recombinant microorganism according to any one of claims 3 to 7 in producing farnesene.